(People's Daily Online)The world's largest insulin preparation and filling plant recently held its foundation stone laying ceremony in China's Tianjin Economic-Technological Development Area (TEDA). The enterprise, being built with an investment of US $381 million from Novo Nordisk of Denmark, will be the company's primary production base in the Asia Pacific region. This is the largest single investment abroad by a Denmark enterprise and it has the capability of providing 500 new jobs for the local area.

Lars Rebin Sorenson, president of Novo Nordisk, expressed his full confidence in China's economic development, noting that the new plant and its Beijing R&D center would become a stronger support platform to change the status quo of diabetes in China.